Arcadia Biosciences (RKDA) Announces Leadership Transition
July 09 2024 - 8:02AM
Business Wire
-- CEO Stan Jacot replaced by CFO Thomas J.
Schaefer --
Arcadia Biosciences, Inc.® (Nasdaq: RKDA), a producer and
marketer of innovative, plant-based health and wellness products,
announced that CEO Stan Jacot has left the company and been
replaced by Thomas J. Schaefer, effective July 5, 2024. Schaefer
was previously Arcadia’s chief financial officer and will be
replaced in that role by Mark Kawakami, Arcadia’s current vice
president of finance.
“On behalf of Arcadia, I would like to thank Stan for his many
contributions to the company,” said Board of Directors Chairman
Kevin Comcowich. “Under his leadership, Arcadia expanded the
GoodWheat brand into three categories, sold the brand to Above
Food, monetized a portion of our wheat IP, revamped Zola coconut
water and divested or exited several unprofitable businesses. We
wish him all the best in the next phase of his career.”
Schaefer is an accomplished executive with more than 20 years of
experience in investments and corporate finance. He began his
career as an equity research analyst and later joined a Fortune 500
company where he helped lead several acquisitions and divestitures.
In 2013, Schaefer moved into consumer products where he led teams,
developed long-range strategies and helped launch new products
across a variety of industries including vitamins and apparel. He
later served as director of finance at Flavor Producers, a
portfolio company owned by private equity firm GTCR that
specialized in beverages and snacks, before joining Arcadia in
2020.
Schaefer earned a bachelor of business administration in
economics and finance from McKendree University and a master of
business administration (MBA) from the Marshall School of Business
at the University of Southern California. He also holds the
Chartered Financial Analyst (CFA) designation.
“T.J. has played a significant role in the company’s transition
from ag research to consumer goods, and he was instrumental in the
development of Project Greenfield, the company’s strategic plan to
unlock the company’s potential and provide a path to
profitability,” said Comcowich. “We welcome his leadership as we
continue to expand the footprint of Zola coconut water, explore
strategic opportunities, monetize our IP and create value for our
shareholders.”
Schaefer’s successor as chief financial officer, Mark Kawakami,
joined Arcadia in 2021, and he has held several key positions, most
recently as the vice president of finance. Kawakami brings more
than 20 years of finance and accounting experience to the role,
with a background in industries such as convenience and retail
grocery, food manufacturing, consumer packaged goods and financial
services. He is a graduate of the University of Southern California
where he earned both a bachelor’s degree and MBA.
About Arcadia Biosciences, Inc.
Since 2002, Arcadia Biosciences (Nasdaq: RKDA) has been
innovating crops to provide high-value, healthy ingredients to meet
consumer demands for healthier choices. With its roots in
agricultural innovation, Arcadia cultivates next-generation
wellness products that make everybody feel good. For more
information, visit arcadiabio.com.
Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, including statements regarding the success of the company’s
long-term strategy, the growth of the company’s Zola business and
the monetization of the company’s intellectual property.
Forward-looking statements are subject to risks and uncertainties
that could cause actual results to differ materially, and reported
results should not be considered as an indication of future
performance. These risks and uncertainties include, but are not
limited to, the risks set forth in Arcadia’s Annual Report on Form
10-K for the year ended December 31, 2023 and other filings Arcadia
makes with the Securities and Exchange Commission. These
forward-looking statements speak only as of the date hereof, and
Arcadia Biosciences, Inc. disclaims any obligation to update these
forward-looking statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240709010359/en/
Sue Wandell ir@arcadiabio.com
Arcadia Biosciences (NASDAQ:RKDA)
Historical Stock Chart
From Oct 2024 to Nov 2024
Arcadia Biosciences (NASDAQ:RKDA)
Historical Stock Chart
From Nov 2023 to Nov 2024